Fig. 4
From: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
PD and PK profiles of LC53-0110 in mice bearing human multiple myeloma xenografts. a MM.1S tumor bearing mice were administered orally with a single dose of LC53-0110 at 50 mg/kg, and the 20S proteasome catalytic activities in tumor and blood were evaluated with CT-L subunit-specific fluorogenic peptide substrates. Data points, mean +/−SE (n = 3). b In the same study, concentration-time profiles of LC53-0110 in plasma, blood, and tumor were determined. Data points, mean +/−SD (n = 3)